Skip to main content
Top
Published in: Rheumatology International 12/2011

01-12-2011 | Original Article

Dietary alpha lipoic acid supplementation prevents synovial inflammation and bone destruction in collagen-induced arthritic mice

Authors: Young-Sool Hah, Mi Jeong Sung, Hye Song Lim, Jin-Su Jun, Yong-Genu Jeong, Hyun-Ok Kim, Junghwan Kim, Haeng Jeon Hur, Munkhtugs Davaatseren, Dae Young Kwon, Sang-Il Lee

Published in: Rheumatology International | Issue 12/2011

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by chronic inflammation and joint destruction. In this study, we investigated whether dietary supplementation with alpha lipoic acid (ALA) suppresses collagen-induced arthritis (CIA) in mice. Mice were randomly divided into three groups: (1) a control CIA group was fed a normal diet, (2) a CIA group was fed a 0.1% ALA diet (average ALA intake of 160 mg/kg/day), and (3) a CIA group was fed a 0.5% ALA diet (average ALA intake of 800 mg/kg/day). The ALA-fed mice showed a decreased incidence and severity of arthritis compared to the normal diet group. Radiographic findings revealed a dramatic decrease in bone destruction, and histological findings showed extensively suppressed pathological changes in the ALA-fed mice. The ALA-fed mice exhibited inhibited generation of tartrate resistant acid phosphatase (TRAP)-positive osteoclasts in vivo. Additionally, ALA-fed mice reduced production of various proinflammatory cytokines and the soluble receptor activator of NF-κB ligand (sRANKL) in the joint tissues and the sera. In conclusion, dietary supplementation with ALA attenuated inflammatory responses and bone destruction in CIA mice.
Literature
1.
go back to reference Pincus T, Sokka T, Wolfe F (2001) Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 44:1234–1236PubMedCrossRef Pincus T, Sokka T, Wolfe F (2001) Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 44:1234–1236PubMedCrossRef
3.
go back to reference Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11PubMedCrossRef Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11PubMedCrossRef
4.
go back to reference Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35–37PubMedCrossRef Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35–37PubMedCrossRef
5.
go back to reference Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, Mukhtar H (1999) Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 96:4524–4529PubMedCrossRef Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, Mukhtar H (1999) Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 96:4524–4529PubMedCrossRef
6.
go back to reference Yun HJ, Yoo WH, Han MK, Lee YR, Kim JS, Lee SI (2008) Epigallocatechin-3-gallate suppresses TNF-alpha -induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol Int 29:23–29PubMedCrossRef Yun HJ, Yoo WH, Han MK, Lee YR, Kim JS, Lee SI (2008) Epigallocatechin-3-gallate suppresses TNF-alpha -induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol Int 29:23–29PubMedCrossRef
7.
go back to reference Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–488PubMedCrossRef Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–488PubMedCrossRef
8.
go back to reference Atzeni F, Sarzi-Puttini P (2009) Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10:1204–1211PubMed Atzeni F, Sarzi-Puttini P (2009) Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10:1204–1211PubMed
9.
10.
go back to reference Roy S, Packer L (1998) Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. Biofactors 8:17–21PubMedCrossRef Roy S, Packer L (1998) Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. Biofactors 8:17–21PubMedCrossRef
11.
go back to reference Goraca A, Józefowicz-Okonkwo G (2007) Protective effects of early treatment with lipoic acid in LPS-induced lung injury in rats. J Physiol Pharmacol 58:541–549PubMed Goraca A, Józefowicz-Okonkwo G (2007) Protective effects of early treatment with lipoic acid in LPS-induced lung injury in rats. J Physiol Pharmacol 58:541–549PubMed
12.
go back to reference Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L (1997) Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 6:321–338PubMedCrossRef Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L (1997) Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 6:321–338PubMedCrossRef
13.
go back to reference Scott BC, Aruoma OI, Evans PJ, O’Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 20:119–133PubMedCrossRef Scott BC, Aruoma OI, Evans PJ, O’Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 20:119–133PubMedCrossRef
14.
go back to reference Zhang WJ, Wei H, Hagen T, Frei B (2007) Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci U S A 104:4077–4082PubMedCrossRef Zhang WJ, Wei H, Hagen T, Frei B (2007) Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci U S A 104:4077–4082PubMedCrossRef
15.
go back to reference Tastekin N, Aydogdu N, Dokmeci D, Usta U, Birtane M, Erbas H, Ture M (2007) Protective effects of L-carnitine and alpha-lipoic acid in rats with adjuvant arthritis. Pharmacol Res 56:303–310PubMedCrossRef Tastekin N, Aydogdu N, Dokmeci D, Usta U, Birtane M, Erbas H, Ture M (2007) Protective effects of L-carnitine and alpha-lipoic acid in rats with adjuvant arthritis. Pharmacol Res 56:303–310PubMedCrossRef
16.
go back to reference Lee EY, Lee CK, Lee KU, Park JY, Cho KJ, Cho YS, Lee HR, Moon SH, Moon HB, Yoo B (2007) Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice. Rheumatol Int 27:225–233PubMedCrossRef Lee EY, Lee CK, Lee KU, Park JY, Cho KJ, Cho YS, Lee HR, Moon SH, Moon HB, Yoo B (2007) Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice. Rheumatol Int 27:225–233PubMedCrossRef
17.
go back to reference Ha H, Lee JH, Kim HN, Kim HM, Kwak HB, Lee S, Kim HH, Lee ZH (2006) Alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J Immunol 176:111–117PubMed Ha H, Lee JH, Kim HN, Kim HM, Kwak HB, Lee S, Kim HH, Lee ZH (2006) Alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J Immunol 176:111–117PubMed
18.
go back to reference Lee SI, Lee SY, Yoon KH, Choi KS, Jang KY, Yoo WH, Kim SH, Choi TH, Park JG (2009) Molecular MR imaging for visualizing ICAM-1 expression in the inflamed synovium of collagen-induced arthritic mice. Korean J Radiol 10:472–480PubMedCrossRef Lee SI, Lee SY, Yoon KH, Choi KS, Jang KY, Yoo WH, Kim SH, Choi TH, Park JG (2009) Molecular MR imaging for visualizing ICAM-1 expression in the inflamed synovium of collagen-induced arthritic mice. Korean J Radiol 10:472–480PubMedCrossRef
19.
go back to reference Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049–5055PubMed Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049–5055PubMed
20.
go back to reference Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef
21.
go back to reference Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269PubMedCrossRef Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269PubMedCrossRef
22.
go back to reference Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790:1149–1160PubMedCrossRef Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790:1149–1160PubMedCrossRef
23.
go back to reference Packer L, Witt EH, Tritschler HJ (1995) Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19:227–250PubMedCrossRef Packer L, Witt EH, Tritschler HJ (1995) Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19:227–250PubMedCrossRef
24.
go back to reference Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R (1998) Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 36:625–628PubMed Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R (1998) Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 36:625–628PubMed
25.
go back to reference Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRef Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRef
26.
go back to reference Cronstein BN (2007) Interleukin-6 -a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 65:S11–S15PubMed Cronstein BN (2007) Interleukin-6 -a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 65:S11–S15PubMed
27.
go back to reference Ragab AA, Nalepka JL, Bi Y, Greenfield EM (2002) Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 283:C679–C687PubMed Ragab AA, Nalepka JL, Bi Y, Greenfield EM (2002) Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 283:C679–C687PubMed
28.
go back to reference Bernatsky S, Hudson M, Suissa S (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46:1157–1160CrossRef Bernatsky S, Hudson M, Suissa S (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46:1157–1160CrossRef
29.
go back to reference Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef
30.
go back to reference Lee MS, Lee MS, Yang CY, Lee SI, Joo MC, Shin BC, Yoo WH, Shin YI (2008) Use of complementary and alternative medicine by rheumatoid arthritis patients in Korea. Clin Rheumatol 27:29–33PubMedCrossRef Lee MS, Lee MS, Yang CY, Lee SI, Joo MC, Shin BC, Yoo WH, Shin YI (2008) Use of complementary and alternative medicine by rheumatoid arthritis patients in Korea. Clin Rheumatol 27:29–33PubMedCrossRef
31.
go back to reference Karatay S, Erdem T, Kiziltunc A, Melikoglu MA, Yildirim K, Cakir E, Ugur M, Aktas A, Senel K (2006) General or personal diet: the individualized model for diet challenges in patients with rheumatoid arthritis. Rheumatol Int 26:556–560PubMedCrossRef Karatay S, Erdem T, Kiziltunc A, Melikoglu MA, Yildirim K, Cakir E, Ugur M, Aktas A, Senel K (2006) General or personal diet: the individualized model for diet challenges in patients with rheumatoid arthritis. Rheumatol Int 26:556–560PubMedCrossRef
32.
go back to reference Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W (2003) Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol Int 23:27–36PubMed Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W (2003) Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol Int 23:27–36PubMed
33.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef
34.
go back to reference Pasceri V, Yeh ET (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100:2124–2126PubMed Pasceri V, Yeh ET (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100:2124–2126PubMed
35.
go back to reference Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA (1995) Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38:1425–1433PubMedCrossRef Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA (1995) Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38:1425–1433PubMedCrossRef
36.
go back to reference Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31(3):171–179PubMedCrossRef Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31(3):171–179PubMedCrossRef
37.
go back to reference Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22:1296–1301PubMedCrossRef Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22:1296–1301PubMedCrossRef
38.
go back to reference Femiano F, Gombos F, Scully C, Busciolano M, De Luca P (2000) Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis 6:274–277PubMedCrossRef Femiano F, Gombos F, Scully C, Busciolano M, De Luca P (2000) Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis 6:274–277PubMedCrossRef
39.
go back to reference Cakatay U, Kayali R (2005) Plasma protein oxidation in aging rats after alpha-lipoic acid administration. Biogerontology 6:87–93PubMedCrossRef Cakatay U, Kayali R (2005) Plasma protein oxidation in aging rats after alpha-lipoic acid administration. Biogerontology 6:87–93PubMedCrossRef
Metadata
Title
Dietary alpha lipoic acid supplementation prevents synovial inflammation and bone destruction in collagen-induced arthritic mice
Authors
Young-Sool Hah
Mi Jeong Sung
Hye Song Lim
Jin-Su Jun
Yong-Genu Jeong
Hyun-Ok Kim
Junghwan Kim
Haeng Jeon Hur
Munkhtugs Davaatseren
Dae Young Kwon
Sang-Il Lee
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1505-3

Other articles of this Issue 12/2011

Rheumatology International 12/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine